ReviewMicroorganisms2026
Gut and Intraplaque Microbiota in Atherosclerosis: Mechanistic Insights and Emerging Therapeutic Targets.
Review in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Atherosclerosis remains a major cause of cardiovascular morbidity and mortality. Growing evidence suggests that microbiota-host interactions contribute to atherosclerosis through systemic and local mechanisms. This review summarizes current evidence on gut microbiota, microbial metabolites, and plaque-associated microbial signals, and discusses their potential therapeutic implications. Gut dysbiosis may contribute to atherosclerosis through multiple metabolite-dependent, immune, vascular, and metabolic pathways. Recent multi-omics and experimental studies further indicate that microbiota influence vascular biology beyond compositional changes alone. In parallel, plaque-associated microbial signals, potentially originating from the oral cavity or gut, may contribute to local inflammation, oxidative stress, necrotic core expansion, and plaque vulnerability. We further discuss a putative gut-oral-intraplaque axis, a potential local microbial metabolite microenvironment within plaques, and possible cross-kingdom interactions between gut fungi and bacteria. Together, these findings support an integrated framework in which microbiota may shape atherosclerosis through interconnected systemic and local pathways, with potential implications for biomarker development and microbiota-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.